Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 8/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639223 | 0.83 | UCHL1 (0.46) | UCHL1S1PR1S1PR3LRRK2PDCD1 | |
| SCHEMBL25124392 | 0.82 | UCHL1 (0.50) | UCHL1GRM5DHPS | |
| SCHEMBL2625808 | 0.78 | HTR2C (0.47) | UCHL1S1PR1S1PR3PDCD1CD274 | |
| SCHEMBL23055771 | 0.78 | GRM5 (0.45) | S1PR1S1PR3GRM5GRM1 | |
| SCHEMBL25124593 | 0.78 | S1PR1 (0.43) | UCHL1S1PR1S1PR3LRRK2PDCD1 | |
| SCHEMBL24783932 | 0.75 | UCHL1 (0.50) | UCHL1S1PR1S1PR3LRRK2ROCK2 | |
| SCHEMBL25124481 | 0.74 | GRM5 (0.32) | UCHL1GRM5 | |
| SCHEMBL24783739 | 0.74 | S1PR1 (0.43) | UCHL1S1PR1S1PR3LRRK2PDCD1 | |
| SCHEMBL25980266 | 0.74 | UCHL1 (0.48) | UCHL1DHPS | |
| SCHEMBL24784006 | 0.72 | ADRA1A (0.45) | S1PR1S1PR3LRRK2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | UCHL1 1759/4885S1PR1 3856/4885S1PR3 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.